Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CGEM
CGEM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CGEM News
Cullinan Therapeutics Reports Promising Clinical Data for CLN-978 and Velinotamig
Jun 10 2026
Newsfilter
Cullinan Therapeutics to Host Immunology Day with Key Updates
Jun 09 2026
NASDAQ.COM
CLN-978 Shows Significant Clinical Benefits in Autoimmune Diseases
Jun 06 2026
Newsfilter
Cullinan Receives FDA Orphan Drug Designation
May 19 2026
NASDAQ.COM
CLN-049 Receives FDA Orphan Drug Designation
May 19 2026
Newsfilter
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978 at EULAR Congress
May 18 2026
Newsfilter
MindWalk Reports Significant Progress in Drug Development
May 18 2026
Newsfilter
Cullinan Therapeutics Reports Q1 Financial Results and Outlook
May 07 2026
seekingalpha
Cullinan Therapeutics Receives FDA Acceptance for Zipalertinib NDA
Apr 28 2026
seekingalpha
Analysis of Cullinan Therapeutics Options Trading
Mar 27 2026
NASDAQ.COM
Cullinan Therapeutics Flags 2026 as Key Year for Clinical Data
Mar 14 2026
Yahoo Finance
Cullinan Therapeutics Reports Wider Q4 Net Loss and R&D Expenses
Mar 11 2026
NASDAQ.COM
Cullinan Therapeutics Q4 Earnings Miss Expectations
Mar 10 2026
seekingalpha
Growth Prospects for the EGFR-NSCLC Market Analyzed
Feb 11 2026
Newsfilter
Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More
Dec 08 2025
Benzinga
Cullinan Therapeutics' CLN-049 Shows 31% Complete Response Rate in R/R AML Patients
Dec 08 2025
Globenewswire
Show More News
